Arian Pano

803 total citations
16 papers, 574 citations indexed

About

Arian Pano is a scholar working on Physiology, Epidemiology and Molecular Biology. According to data from OpenAlex, Arian Pano has authored 16 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Physiology, 5 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Arian Pano's work include Lysosomal Storage Disorders Research (9 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Trypanosoma species research and implications (4 papers). Arian Pano is often cited by papers focused on Lysosomal Storage Disorders Research (9 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Trypanosoma species research and implications (4 papers). Arian Pano collaborates with scholars based in United States, United Kingdom and Brazil. Arian Pano's co-authors include David Whiteman, Donna R. Grogan, Daniel P. Judge, Rodney H. Falk, Steven R. Zeldenrust, Ann Barbier, Antony Y. Kim, Ayan R. Patel, Matthew J. Maurer and Frederick L. Ruberg and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

In The Last Decade

Arian Pano

15 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arian Pano United States 9 262 185 182 173 136 16 574
Takayoshi Hirota Japan 16 184 0.7× 138 0.7× 76 0.4× 687 4.0× 48 0.4× 54 858
Roberta Mussinelli Italy 11 428 1.6× 58 0.3× 49 0.3× 123 0.7× 73 0.5× 22 500
Annalisa Madeo Italy 10 154 0.6× 109 0.6× 81 0.4× 12 0.1× 89 0.7× 24 365
Joseph P. Donnelly United States 10 534 2.0× 48 0.3× 99 0.5× 73 0.4× 146 1.1× 16 610
Lars Wikström Sweden 11 430 1.6× 124 0.7× 75 0.4× 33 0.2× 32 0.2× 13 482
Havva Yazıcı Türkiye 9 184 0.7× 55 0.3× 36 0.2× 13 0.1× 153 1.1× 48 527
Thomas Loew United States 9 105 0.4× 164 0.9× 340 1.9× 6 0.0× 121 0.9× 14 623
K. Nicole Weaver United States 12 232 0.9× 34 0.2× 43 0.2× 38 0.2× 31 0.2× 48 454
Pedro A. deAlarcon United States 5 33 0.1× 72 0.4× 185 1.0× 31 0.2× 41 0.3× 8 446
Björn Pilebro Sweden 13 449 1.7× 29 0.2× 101 0.6× 109 0.6× 78 0.6× 28 516

Countries citing papers authored by Arian Pano

Since Specialization
Citations

This map shows the geographic impact of Arian Pano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arian Pano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arian Pano more than expected).

Fields of papers citing papers by Arian Pano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arian Pano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arian Pano. The network helps show where Arian Pano may publish in the future.

Co-authorship network of co-authors of Arian Pano

This figure shows the co-authorship network connecting the top 25 collaborators of Arian Pano. A scholar is included among the top collaborators of Arian Pano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arian Pano. Arian Pano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
3.
Pupim, Lara B., Kristin Hudock, Joshua L. Denson, et al.. (2021). LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION. Annals of the Rheumatic Diseases. 80. 198–199. 4 indexed citations
4.
Klein, Allan L., Massimo Imazio, Paul Cremer, et al.. (2020). Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 384(1). 31–41. 194 indexed citations
5.
Koningsbruggen‐Rietschel, Silke van, Katja Conrath, Rainald Fischer, et al.. (2019). GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). Journal of Cystic Fibrosis. 19(2). 292–298. 10 indexed citations
6.
Giugliani, Roberto, Paul Harmatz, Simon Jones, et al.. (2017). Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. Molecular Genetics and Metabolism Reports. 12. 2–7. 15 indexed citations
7.
Göker-Alpan, Özlem, Nicola Longo, Timothy J. McDonald, et al.. (2016). An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy. Drug Design Development and Therapy. 10. 1771–1771. 18 indexed citations
8.
Hendriksz, Christian J., Joseph Muenzer, Adeline Vanderver, et al.. (2015). Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment. SHILAP Revista de lepidopterología. 5. 103–106. 27 indexed citations
9.
Pano, Arian, et al.. (2015). Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). Orphanet Journal of Rare Diseases. 10(1). 50–50. 25 indexed citations
10.
Hendriksz, Christian J., Joseph Muenzer, Barbara K. Burton, et al.. (2015). A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients With Hunter Syndrome. SHILAP Revista de lepidopterología. 3. 4077971742–4077971742. 8 indexed citations
11.
Pano, Arian, Özlem Göker-Alpan, Nicola Longo, et al.. (2014). Safety and effect of open-label agalsidase alfa in treatment-naïve children with Fabry disease. Molecular Genetics and Metabolism. 111(2). S84–S84. 1 indexed citations
12.
Hendriksz, Christian J., Joseph Muenzer, Adeline Vanderver, et al.. (2014). Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment. Molecular Genetics and Metabolism. 111(2). S54–S54. 1 indexed citations
13.
14.
Giugliani, Roberto, Wuh‐Liang Hwu, Anna Tylki‐Szymańska, David Whiteman, & Arian Pano. (2013). A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genetics in Medicine. 16(6). 435–441. 31 indexed citations
15.
Ruberg, Frederick L., Matthew J. Maurer, Daniel P. Judge, et al.. (2012). Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal. 164(2). 222–228.e1. 189 indexed citations
16.
Falk, Rodney H., Matthew Maurer, Savitri Fedson, et al.. (2011). Tafamidis Stabilizes Transthyretin and Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy. Journal of Cardiac Failure. 17(8). S56–S56. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takayoshi Hirota Breakdown of academic impact, for papers by Roberta Mussinelli Breakdown of academic impact, for papers by Annalisa Madeo Breakdown of academic impact, for papers by Joseph P. Donnelly Breakdown of academic impact, for papers by Lars Wikström Breakdown of academic impact, for papers by Havva Yazıcı Breakdown of academic impact, for papers by Thomas Loew Breakdown of academic impact, for papers by K. Nicole Weaver Breakdown of academic impact, for papers by Pedro A. deAlarcon Breakdown of academic impact, for papers by Björn Pilebro
Rankless by CCL
2026